Literature DB >> 19766630

Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA.

Daiju Iwata1, Mizuki Kitamura, Nobuyoshi Kitaichi, Yoshinari Saito, Shigeyuki Kon, Kenichi Namba, Junko Morimoto, Akiko Ebihara, Hirokuni Kitamei, Kazuhiko Yoshida, Susumu Ishida, Shigeaki Ohno, Toshimitsu Uede, Kazunori Onoé, Kazuya Iwabuchi.   

Abstract

Osteopontin (OPN) is elevated during the progression of experimental autoimmune uveoretinitis (EAU) in C57BL/6 (B6) mice. Furthermore, EAU symptoms are ameliorated in OPN knockout mice or in B6 mice treated with anti-OPN antibody (M5). Recently, OPN has been shown to promote the Th1 response not only in the extracellular space as a secretory protein but also in cytosol as a signaling component. Thus, we attempted to reduce OPN in both compartments by using a small interfering RNA (siRNA) targeting the OPN coding sequence (OPN-siRNA). EAU was induced in B6 mice by immunization with human interphotoreceptor retinoid-binding protein (hIRBP) peptide sequence 1-20. The OPN- or control-siRNA was administered with hydrodynamic methods 24 h before and simultaneously with immunization (prevention regimen). When plasma OPN levels were quantified following siRNA administration with the prevention regimen, the level in the OPN-siRNA-treated group was significantly lower than that in the control-siRNA-treated group. Accordingly, the clinical and histopathological scores of EAU were significantly reduced in B6 mice when siRNA caused OPN blockade. Furthermore, TNF-alpha, IFN-gamma, IL-2, GM-CSF and IL-17 levels in the culture supernatants were markedly suppressed in the OPN-siRNA-treated group, whereas the proliferative responses of T lymphocytes from regional lymph nodes against immunogenic peptides was not significantly reduced. On the other hand, the protection was not significant if the mice received the OPN-siRNA treatment on day 7 and day 8 after immunization when the clinical symptoms appeared overt (reversal regimen). Our results suggest that OPN blockade with OPN-siRNA can be an alternative choice for the usage of anti-OPN antibody and controlling uveoretinitis in the preventive regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19766630     DOI: 10.1016/j.exer.2009.09.008

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema.

Authors:  Ming Shan; Xiaoyi Yuan; Li-Zhen Song; Luz Roberts; Nazanin Zarinkamar; Alexander Seryshev; Yiqun Zhang; Susan Hilsenbeck; Seon-Hee Chang; Chen Dong; David B Corry; Farrah Kheradmand
Journal:  Sci Transl Med       Date:  2012-01-18       Impact factor: 17.956

3.  Increased vitreous levels of B cell activation factor (BAFF) and soluble interleukin-6 receptor in patients with macular edema due to uveitis related to Behçet's disease and sarcoidosis.

Authors:  Atsunobu Takeda; Eiichi Hasegawa; Nobuyo Yawata; Shoji Notomi; Keijiro Ishikawa; Yusuke Murakami; Toshio Hisatomi; Kazuhiro Kimura; Koh-Hei Sonoda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-01       Impact factor: 3.535

Review 4.  New options for uveitis treatment.

Authors:  Yu He; Song-Bai Jia; Wei Zhang; Jing-Ming Shi
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

5.  Osteopontin and fibronectin levels are decreased in vitreous of autoimmune uveitis and retinal expression of both proteins indicates ECM re-modeling.

Authors:  Cornelia A Deeg; Christina Eberhardt; Florian Hofmaier; Barbara Amann; Stefanie M Hauck
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

Review 6.  Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases.

Authors:  Nausicaa Clemente; Davide Raineri; Giuseppe Cappellano; Elena Boggio; Francesco Favero; Maria Felicia Soluri; Chiara Dianzani; Cristoforo Comi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  J Immunol Res       Date:  2016-12-20       Impact factor: 4.818

7.  Retinal microglia initiate neuroinflammation in ocular autoimmunity.

Authors:  Yoko Okunuki; Ryo Mukai; Takeshi Nakao; Steven J Tabor; Oleg Butovsky; Reza Dana; Bruce R Ksander; Kip M Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-25       Impact factor: 11.205

8.  Osteopontin is a biomarker for early autoimmune uveoretinitis.

Authors:  Jeongtae Kim; Meejung Ahn; Yuna Choi; Jiyoon Chun; Kyungsook Jung; Akane Tanaka; Hiroshi Matsuda; Taekyun Shin
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

Review 9.  Pharmacotherapy for uveitis: current management and emerging therapy.

Authors:  Robert J Barry; Quan Dong Nguyen; Richard W Lee; Philip I Murray; Alastair K Denniston
Journal:  Clin Ophthalmol       Date:  2014-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.